نتایج جستجو برای: ژن kras

تعداد نتایج: 23037  

Journal: :Cell 2015
Felix Dietlein Bastian Kalb Mladen Jokic Elisa M. Noll Alexander Strong Lars Tharun Luka Ozretić Helen Künstlinger Kato Kambartel Winfried J. Randerath Christian Jüngst Anna Schmitt Alessandro Torgovnick André Richters Daniel Rauh Florian Siedek Thorsten Persigehl Cornelia Mauch Jirina Bartkova Allan Bradley Martin R. Sprick Andreas Trumpp Roland Rad Dieter Saur Jiri Bartek Jürgen Wolf Reinhard Büttner Roman K. Thomas H. Christian Reinhardt

KRAS is one of the most frequently mutated oncogenes in human cancer. Despite substantial efforts, no clinically applicable strategy has yet been developed to effectively treat KRAS-mutant tumors. Here, we perform a cell-line-based screen and identify strong synergistic interactions between cell-cycle checkpoint-abrogating Chk1- and MK2 inhibitors, specifically in KRAS- and BRAF-driven cells. M...

Journal: :iranian journal of pathology 2016
mehrdad payandeh masoud sadeghi edris sadeghi

colorectal cancer (crc) metastasis to the thyroid gland is rare. here wereport a 45 yr-old man in western iran referred to hematology clinic, kermanshah city, iran in march 2014 with complaint of exertional dyspnea, multi-nodular goiter as well as complaint of exertional dyspnea, and multi-nodular goiter. his history included a low anterior resection of rectum in 9 months ago for a high-risk st...

2011
Noriaki Sunaga David S. Shames Luc Girard Michael Peyton Jill E. Larsen Hisao Imai Junichi Soh Mitsuo Sato Noriko Yanagitani Kyoichi Kaira Yang Xie Adi F. Gazdar Masatomo Mori John D. Minna

Oncogenic KRAS is found inmore than 25% of lung adenocarcinomas, the major histologic subtype of non– small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown selective for oncogenic KRAS. As expected, stable knockdown of oncogenic KRAS led to inhibition of in vitro and in vivo tumor growth in the KRAS-muta...

Journal: :International journal of oncology 2010
Alenka Licar Petra Cerkovnik Janja Ocvirk Srdjan Novakovic

KRAS mutations are proved as a predictor of response to EGFR-targeted therapies for patients with metastatic colorectal cancer. For identifying the wild-type KRAS (wt-KRAS) responder subset of patients who will benefit from novel agents our laboratory has introduced the TheraSreen K-RAS Mutation Kit(R) an allele-specific RT-PCR based assay. Our aim is to describe the validation procedure of thi...

2016
Ha Yong Song Marco Biancucci Hong-Jun Kang Carol O'Callaghan Seong-Hoon Park Daniel R. Principe Haiyan Jiang Yufan Yan Karla Fullner Satchell Kirtee Raparia David Gius Athanassios Vassilopoulos

The observation that cellular transformation depends on breaching a crucial KRAS activity threshold, along with the finding that only a small percentage of cellsharboring KRAS mutations are transformed, support the idea that additional, not fully uncovered, regulatory mechanisms may contribute to KRAS activation. Here we report that KrasG12D mice lacking Sirt2 show an aggressive tumorigenic phe...

Journal: :Cancer research 2009
Kevin Adrian Matthew J Strouch Qinghua Zeng Morgan R Barron Eric C Cheon Akilesh Honasoge Yanfei Xu Sharbani Phukan Maureen Sadim David J Bentrem Boris Pasche Paul J Grippo

To dissect the role of constitutively altered Tgfbr1 signaling in pancreatic cancer development, we crossed Elastase-Kras(G12D) (EL-Kras) mice with Tgfbr1 haploinsufficient mice to generate EL-Kras/Tgfbr1(+/-) mice. Mice were euthanized at 6 to 9 months to compare the incidence, frequency, and size of precancerous lesions in the pancreas. Only 50% of all EL-Kras/Tgfbr1(+/-) mice developed prein...

Journal: :Oncology reports 2014
Tomokazu Kishiki Hiroaki Ohnishi Tadahiko Masaki Kouki Ohtsuka Yasuo Ohkura Jyunji Furuse Masanori Sugiyama Takashi Watanabe

Reports indicate that, even in KRAS-mutated colon cancer, there are subsets of patients who benefit from anti-EGFR monoclonal antibody (MoAb) treatment. The aim of the present study was to identify genetic profiles that contribute to the responsiveness of metastatic colorectal cancer (mCRC) to anti-EGFR MoAb. We retrospectively evaluated the efficacy of anti-EGFR MoAb in mCRC patients with KRAS...

2017
Zoltan Lohinai Thomas Klikovits Judit Moldvay Gyula Ostoros Erzsebet Raso Jozsef Timar Katalin Fabian Ilona Kovalszky István Kenessey Clemens Aigner Ferenc Renyi-Vamos Walter Klepetko Balazs Dome Balazs Hegedus

Current guidelines lack comprehensive information on the metastatic site-specific role of KRAS mutation in lung adenocarcinoma (LADC). We investigated the effect of KRAS mutation on overall survival (OS) in this setting. In our retrospective study, 500 consecutive Caucasian metastatic LADC patients with known KRAS mutational status were analyzed after excluding 32 patients with EGFR mutations. ...

2016
Difan Zheng Rui Wang Yang Zhang Yunjian Pan Xinghua Cheng Chao Cheng Shanbo Zheng Hang Li Ranxia Gong Yuan Li Xuxia Shen Yihua Sun Haiquan Chen

BACKGROUND We performed this retrospective study to identify the prevalence of KRAS mutation in Chinese populations and make a comprehensive investigation of the clinicopathological features of KRAS mutation in these patients. PATIENTS AND METHODS Patients from 2007 to 2013 diagnosed with primary lung adeno-carcinoma who received a radical resection were examined for KRAS, EGFR, HER2, BRAF mu...

2017
Choong Eun Jin Seung-Seop Yeom Bonhan Koo Tae Yoon Lee Jeong Hoon Lee Yong Shin Seok-Byung Lim

Although KRAS mutational status testing is becoming a companion diagnostic tool for managing patients with colorectal cancer (CRC), there are still several difficulties when analyzing KRAS mutations using the existing assays, particularly with regard to low sensitivity, its time-consuming, and the need for large instruments. We developed a rapid, sensitive, and specific mutation detection assay...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید